Previous studies have suggested that hypertension in HIV-positive individuals is associated primarily with traditional risk factors such as older age, diabetes and dyslipidaemia. However, controversy remains as to whether exposure to antiretroviral (ARV) drugs poses additional risk, and we investigated this question in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort.
Introduction
Over the last two decades, cardiovascular disease (CVD) has emerged as a leading cause of morbidity and mortality in HIV-positive individuals [1] [2] [3] . The increased prevalence of CVD is a consequence of increased life expectancy resulting from the widespread use of effective combination antiretroviral therapy (cART) [1] [2] [3] , the high prevalence of traditional CVD risk factors (including hypertension) [4] [5] [6] and the contribution of HIV-related factors [7] [8] [9] .
The prevalence of hypertension is higher in HIV-positive than HIV-negative individuals [10, 11] , and is increasing [12] . Hypertension in HIV-positive individuals has been linked to traditional CVD risk factors such as diabetes, renal impairment, older age, male gender, black African ethnicity, dyslipidaemia and high body mass index (BMI) [12] [13] [14] [15] [16] . Furthermore, factors related to HIV infection, such as immunosuppression, inflammation, increased arterial stiffness, fat redistribution and lipodystrophy, may also contribute to an increased risk of hypertension [17] [18] [19] [20] .
Controversy remains as to whether exposure to antiretroviral (ARV) drugs poses an additional risk for the development of hypertension. While some studies have reported an increased risk of hypertension in those exposed to cART overall [21] [22] [23] [24] [25] , others have not observed any such association [12, 13, [26] [27] [28] [29] . A previous analysis from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study in 2005 showed no clear association between exposure to ARV drugs and the risk of hypertension, although traditional CVD risk factors were significant predictors of hypertension [13] .
Given the increased life expectancy of people living with HIV, it is important to continuously improve our understanding of CVD risk factors so as to recommend appropriate preventative measures. Our aim was to capitalize on the additional follow-up that is now available in the D:A:D study to re-investigate the potential associations between exposure to individual ARV drugs and the risk of hypertension, as well as to identify non-ARV predictors of hypertension.
Materials and methods

Materials
The D:A:D study is an observational, multinational cohort collaboration including > 49 000 HIV-positive individuals from 11 cohorts across Europe, Australia and the USA. The primary aim of the study is to investigate potential associations between ARV drugs and CVD and other clinical events. Data are collected prospectively during routine clinic visits; the data set includes information on demographic factors, AIDS-related events and deaths, known risk factors for CVD including blood pressure (BP), laboratory markers for monitoring HIV infection and CVD, ARV drugs and treatments that influence CVD and CVD risk.
Definition of hypertension
Hypertension was defined to have occurred on the earliest date of the following events: two consecutive systolic blood pressure (SBP) measurements > 140 mmHg and/or diastolic blood pressure (DBP) measurements > 90 mmHg [30] (with the date of the first raised measurement taken as the diagnosis date); one single SBP measurement > 140 mmHg and/or DBP measurement > 90 mmHg with use of anti-hypertensive drugs or angiotensin converting enzyme inhibitors (ACEIs) within 6 months of this measurement (with the date of the first BP measurement again taken as the diagnosis date); or initiation of anti-hypertensive drugs/ACEIs without a recorded high BP (with the date of initiation taken as the diagnosis date). Blood pressure was measured as part of regular study visits within the participating clinic sites of the participating cohorts.
February 2013, the administrative censoring date for the present analysis.
Individuals with fewer than two SBP or DBP measurements during follow-up (and no initiation of anti-hypertensive drugs or ACEIs), those with < 6 months of follow-up and those with pre-existing hypertension and/ or receiving anti-hypertensive treatment at D:A:D entry were excluded from analyses. The incidence of hypertension was determined in the remaining individuals overall and in strata defined by demographic, metabolic and HIV-related factors. In particular, strata were defined by levels of cumulative exposure to each of the 18 ARV drugs that were commonly prescribed: stavudine (d4T), didanosine (ddI), zalcitabine (ddC), zidovudine (ZDV), lamivudine (3TC), abacavir (ABC), emtricitabine (FTC), tenofovir (TDF), efavirenz (EFV), nevirapine (NVP), lopinavir/ritonavir (LPV/r), ritonavir (RTV), fosamprenavir/ritonavir (fAPV/r), atazanavir (ATV), indinavir/ritonavir (IDV/r), nelfinavir (NFV), saquinavir/ritonavir (SQV/r) and darunavir/ritonavir (DRV/r). Our assessment of cumulative exposure to each drug also included any exposure prior to D:A:D enrolment, allowing us to include cumulative exposure to several ARV drugs that are no longer in widespread use.
We initially investigated unadjusted associations with incident hypertension using Poisson regression models. As in previous analyses of the study, each individual's follow-up was split into a series of consecutive 1-month periods and his/her clinical, immunological and virological status at the start of each period was established. Thus, cumulative exposure to each ARV drug was assessed in a time-updated manner in these models.
Predictors of hypertension were then identified using the following staged model-building approach. Firstly, we fitted a model that included time-updated covariates for exposure to each of the ARV drugs (each covariate was scaled so that the estimate reflected the association with an additional 5 years of exposure to the drug). We then used a backwards selection process to remove drugs from the model that were not independently associated with hypertension risk (note that this model-building step occurred prior to adjustment for non-ARV confounders); this parsimonious model was then taken forward for confounder adjustment. The first set of adjustments included both fixed (gender, ethnicity, participating cohort and mode of HIV acquisition) and time-updated (age, smoking status, calendar year and a previous AIDS diagnosis) covariates. None of these factors were considered to lie on the causal pathway between ARV exposure and hypertension development. Next, we additionally included adjustment for metabolic factors [total cholesterol (TC), triglycerides (TG), use of lipid-lowering drugs (LLDs), lipodystrophy, BMI, diabetes and estimated glomerular filtration rate (eGFR)] that were potentially on the causal pathway to investigate whether these factors could mediate any associations (with all covariates being considered as time-updated covariates). Finally, we additionally included adjustment for other HIV-related factors, notably the latest/current HIV RNA viral load (VL) and CD4 count, both as time-updated covariates.
Sensitivity analyses were conducted in which we restricted the analyses to individuals currently on ARV drugs, and in which we used modified definitions of hypertension that were based either on the initiation of anti-hypertensives/ACEIs only or on the presence of elevated BP measurements only. Of the factors associated with hypertension in the fully adjusted multivariable model (Tables 2a,b) , the highest point estimates were observed for male gender, older age, black African ethnicity, HIV acquisition through IDU, previous AIDS, diabetes, a high TC or TG level, use of LLDs, lipodystrophy, BMI > 30 kg/m 2 and a low eGFR. We did not observe any association between current smoking and the risk of hypertension. CD4 count < 100 cells/lL was the strongest HIV-related predictor of hypertension, whereas a VL > 100 000 copies/mL was associated with a decreased risk of hypertension.
Results
Most
Results were consistent in sensitivity analyses restricted to individuals currently on ARVs, and when redefining hypertension on the basis of either initiating anti-hypertensives/ACEIs or having elevated BP measurements only.
Discussion
While several studies have investigated the potential association between cART and the risk of hypertension, few have been able to investigate associations with individual ARVs because of limited size and/or follow-up. Using data from a large, heterogeneous cohort with information on a wide range of demographic, metabolic and HIV-related factors, we did not find evidence of any strong associations between specific ARV drugs and an increased risk of hypertension. We did, however, document associations with many of the established risk factors for hypertension in the general population, such as older age, male gender, diabetes, high BMI, black African ethnicity and low eGFR, in addition to severe immunosuppression. Our findings are consistent with previous D:A:D findings [13] , although our results are based on a substantially longer duration of follow-up and a wider range of ARV drugs.
Prior studies on hypertension in HIV-positive individuals have generally been cross-sectional, and reported conflicting prevalence data [10, 11, 22, 28, 29] compared with the general population. In our current study, the incidence of hypertension was lower than previously reported [12] , although this study included a higher proportion of individuals of black African ethnicity and uninsured participants who may not have had access to preventive CVD care. Prior studies considering associations between ARV exposure and hypertension have also reported divergent findings, probably as a consequence of differences in study design, study populations, the definition of hypertension and the range of demographic, metabolic and HIV-related factors available for adjustment. Several studies have demonstrated an increased risk of hypertension with cumulative exposure to ARVs [21] [22] [23] [24] ; after adjustment, Baekken et al. found that individuals exposed to > 5 years of cART had higher rates of hypertension than those of age-, sex-and BMI-matched HIV-negative controls and ART-na€ ıve HIV-positive individuals [21] . Two other studies demonstrated an increased risk of hypertension in those with longer exposure to cART [22, 24] , but these studies did not adjust for metabolic factors [22] , or eGFR, dyslipidaemia or HIV-related factors, respectively [24] . Although these studies demonstrated a potential correlation between cART exposure and hypertension, the explanatory mechanisms are unclear. The ARV effect may be mediated through metabolic side effects such as diabetes, dyslipidaemia and body fat changes, which have previously been associated with some ARVs [9, 20, [31] [32] [33] , or it could be mediated directly through changes in endothelial function. An association between cART and aortic stiffness, a risk factor for hypertension, was observed in individuals treated with protease inhibitors in one study [34] , although not in another [19] , whereas impaired endothelial function has been associated with ABC [35] .
A recent meta-analysis found an association between exposure to cART and an increased risk of hypertension (odds ratio 1.68) [23] . However, this meta-analysis was limited by the small number of included studies and the lack of included multivariable analyses. Nduka et al. [36] used propensity score methods to demonstrate a high probability that the link between cART and increased BP in sub-Saharan Africa was causal. It is possible that the use of older ARVs is potentially more harmful in the black African population, which has a higher hypertension risk than the white population [37] .
Conversely, several studies have demonstrated a lack of an independent association between cumulative exposure to cART and hypertension [12, 20, [26] [27] [28] . One study suggested that an increased prevalence of hypertension among cART-treated individuals might be driven by abdominal obesity and d4T-induced peripheral lipoatrophy [20] . Thus, most studies that have demonstrated an association with cART have suggested that this is likely to be a consequence of the metabolic side effects of ARVs.
The lack of association between individuals ARVs and risk of hypertension in our study argues that the effects seen in univariable models were mainly explained by confounding with demographic and metabolic factors. Only two ARVs, NVP and IDV/r, remained associated with a significantly increased risk of hypertension, although the adjusted association was small and of limited clinical relevance. In contrast to previous findings [20] , we did not observe an independent association between exposure to d4T and hypertension. This may be attributable to the fact that lipodystrophy is more inconsistently reported in participating D:A:D cohorts, that our study population may have been at lower risk of lipodystrophy when d4T was being used, or that restriction of the previous study to individuals aged > 45 years [20] may have selected a group of long-term survivors with previous lipodystrophy.
We have recently demonstrated that exposure to DRV/ r, one of the newer ARVs, is associated with an increased risk of CVD [38] ; the findings of the present study, which demonstrate a reduced risk of hypertension in those with longer DRV/r exposure, suggest that this CVD association is unlikely to be mediated by hypertension.
The strongest demographic/metabolic predictors of hypertension in our study were male gender, older age, black African ethnicity, diabetes, dyslipidaemia, use of LLDs, a high BMI and a low eGFR, consistent with previous findings [12] [13] [14] [15] [16] . Current or previous smoking was not found to be a predictor; although smoking is an important risk factor for arteriosclerosis and can cause arterial stiffness which could lead to hypertension, there is limited evidence of a direct causal relationship between smoking and hypertension [39] . This lack of association with smoking has been observed in other studies [12, 20, 21, 28] . Of the HIV-related factors, a CD4 count < 100 cells/lL was the strongest predictor. Surprisingly, a high VL was associated with a decreased risk of hypertension, consistent with the direction of association in our previous analyses [13] . As the majority of participating individuals were on cART, those with a high VL may have been individuals who were experiencing difficulties in taking or adhering to cART; these individuals may be less likely to engage regularly with care or BP monitoring, making it harder to diagnose hypertension. Furthermore, individuals with high VLs may also have lower BP as a consequence of severe HIV-related illness.
The lack of a direct association with cART in our study provides reassurance that, in addition to preventing immunosuppression by prompt initiation of cART, screening policies and preventive measures used in the general population are also applicable in HIV-positive individuals. The The Systolic Blood Pressure Intervention Trial (SPRINT) study [40] demonstrated that more intensive BP control in high CVD risk individuals, which targeted a systolic BP < 120 mmHg rather than < 140 mmHg, reduced the incidence of adverse CVD events such as myocardial infarction and stroke [40] . As hypertension is prevalent in HIV-positive individuals, it is likely that this more aggressive intervention policy should also be applied to those living with HIV, to identify those eligible for anti-hypertensive and LLD therapy. Finally, other nonpharmacological interventions, such as dietary, lifestyle and smoking cessation advice, use of newer ARVs with improved metabolic profiles and the prompt initiation of cART in newly infected individuals, are also of importance.
Limitations
Some limitations to our study should be acknowledged. BP measurements were not standardized across cohorts, which may have introduced variability. Furthermore, errors in BP measurement might have led to an over-or underestimation of hypertension incidence, introducing dilution bias which may have led to erroneous negative findings. However, given the strong associations with traditional risk factors, we do not believe that this can explain a lack of association with the ARV drugs in our study. We did not have an HIVnegative control group, and we were unable to investigate newer ARVs (integrase or entry inhibitors) because of limited follow-up among individuals exposed to these drugs. While we cannot exclude the possibility of delayed effects of any of the ARVs, we did not see any evidence to support this. Finally, although we adjusted for known risk factors for hypertension, we cannot exclude the possibility that our findings were affected by unmeasured or unknown confounders, or residual confounding with ethnicity (information on ethnicity was unavailable for some individuals as collection of the information is prohibited in several participating cohorts). ARVs reported to be associated with metabolic side effects might have been avoided in individuals considered to be at high CVD risk, which may have masked potentially true associations.
Conclusions
We did not find evidence for any significant clinically relevant independent associations between exposure to any of the investigated ARV drugs and hypertension risk, but did confirm the importance of traditional risk factors. Our findings provide reassurance that, in addition to preventing immunosuppression in HIV-positive individuals, screening policies and preventive measures for hypertension in HIV-positive persons should follow the algorithms used for the general population. However, continued pharmaco-vigilance is warranted for newer ARV drugs not investigated in this study.
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Cohort members
The current members of the 11 cohorts are as follows.
ATHENA (AIDS Therapy Evaluation Project Netherlands)
EuroSIDA (multinational) 
